Comparison of the efficacy and possible side effects of high and standard doses of rifampin in the treatment of brucellosis
- Conditions
- brucellosis.Brucellosis
- Registration Number
- IRCT20201015049030N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 55
Isolation of Brucella in culture of blood or bone marrow or other body fluids
Positive Brucella PCR test in blood and / or body fluids or tissue samples
Wright title equal to or greater than 160/1
The title of Combs Wright is at least two levels higher than Wright
Age less than 14 years-
Intrinsic or acquired immunodeficiency
Simultaneous with advanced or chronic heart, lung, liver and kidney diseases
Pregnancy-
Taking oral contraceptives
Consumption of phenytoin
History of receiving anti-brucellosis treatment in a recent month for more than a week
Infection with local forms of malaria, endocarditis, spondylitis, meningitis, etc.
Taking antibiotics more than 7 days before the visit
History of allergy to doxycycline or rifampin
General malaise so that the patient is not able to take medication orally.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment. Timepoint: The second, fourth, sixth and eighth weeks after starting treatment and up to three months after treatment. Method of measurement: Patients are divided into the following three groups in terms of response to treatment:1- Complete recovery: Complete recovery is considered when the symptoms disappear with treatment and by the end of the follow-up dose, the symptoms do not return and clinical signs are not found in favor of brucellosis.Relapse: It is when the symptoms have disappeared with treatment, but in the one-year follow-up period after the end of treatment, the symptoms have returned.3 - persistence of infection or treatment failure: is when the signs and symptoms of the disease at the end of treatment are still present.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: The second, fourth, sixth and eighth weeks after starting treatment and up to three months after treatment. Method of measurement: Presence or absence of side effects.;Wright laboratory test. Timepoint: The second, fourth, sixth and eighth weeks after starting treatment and up to three months after treatment. Method of measurement: Based on the results of the Wright laboratory test.;Coombs test. Timepoint: The second, fourth, sixth and eighth weeks after starting treatment and up to three months after treatment. Method of measurement: Based on the results of the Coombs laboratory test.